TRT-AGT1-2
geneOn this page
Also known as tRNA-Thr-AGT-1-2
Summary
TRT-AGT1-2 (tRNA-Thr (anticodon AGT) 1-2, HGNC:34785) is a gene on chromosome 17p13.1.
At a glance
- Clinical variants (ClinVar): 2 total
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:34785 |
| Approved symbol | TRT-AGT1-2 |
| Name | tRNA-Thr (anticodon AGT) 1-2 |
| Location | 17p13.1 |
| Locus type | RNA, transfer |
| Status | Approved |
| Aliases | tRNA-Thr-AGT-1-2 |
| Entrez | 100189222 |
| RNAcentral | URS00000A1A88 — tRNA, 74 nt, 127 organism(s) |
Gene structure
Transcript identifiers
Ensembl transcripts: 0
RefSeq mRNA: 0 — MANE Select: None
Canonical transcript exons
None — 0 exons
Expression profiles
Top tissues by expression
0 total, by Bgee expression score (0-100, higher = more expressed):
Regulation
Is transcription factor: no
Cross-species orthologs
0 orthologs
Protein
Protein identifiers
Canonical reviewed UniProt: None (reviewed: )
All UniProt accessions (0):
RefSeq proteins (0): (*=MANE)
Domains & families (InterPro)
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 0 (showing top):
GO Biological Process (0):
GO Molecular Function (0):
GO Cellular Component (0):
Protein interactions and networks
STRING
0 interactions, top by confidence (×1000):
IntAct
0 interactions, top by confidence:
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
2 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 2 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
0 predictions. Top by Δscore:
AlphaMissense
0 scored. Top likely-pathogenic:
Disease associations
OMIM: gene `` | disease phenotypes: MIM:127550
GenCC curated gene-disease
Mondo (1): dyskeratosis congenita (MONDO:0015780)
Orphanet (1): Dyskeratosis congenita (Orphanet:1775)
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
MeSH disease descriptors (1)
| Descriptor | Name | Tree numbers |
|---|---|---|
| D019871 | Dyskeratosis Congenita | C15.378.190.223.500.750; C16.131.831.150; C16.320.322.108; C16.320.850.235; C17.800.804.150; C17.800.827.235 |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 0 entries
Clinical trials (associated diseases)
18 trials via MONDO — disease-level, not drug-specific.
| Trial | Phase | Status | Title |
|---|---|---|---|
| NCT00004787 | PHASE2 | COMPLETED | Phase II Pilot Study of Granulocyte Colony-Stimulating Factor for Inherited Bone Marrow Failure Syndromes |
| NCT01659606 | PHASE2 | ACTIVE_NOT_RECRUITING | Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita |
| NCT03579875 | PHASE2 | RECRUITING | Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders |
| NCT04232085 | PHASE2 | RECRUITING | Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures |
| NCT04638517 | PHASE2 | TERMINATED | The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis |
| NCT01917708 | PHASE1 | COMPLETED | Bone Marrow Transplant With Abatacept for Non-Malignant Diseases |
| NCT06477614 | PHASE1 | RECRUITING | Anti-cancer DC Cell Vaccination to Treat Solid Tumors |
| NCT06817590 | PHASE1 | RECRUITING | Nucleoside Therapy in Patients With Telomere Biology Disorders |
| NCT00455312 | PHASE2/PHASE3 | COMPLETED | Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA |
| NCT01001598 | PHASE1/PHASE2 | TERMINATED | Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita |
| NCT00027274 | Not specified | RECRUITING | Cancer in Inherited Bone Marrow Failure Syndromes |
| NCT00499070 | Not specified | COMPLETED | Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment |
| NCT01319851 | Not specified | TERMINATED | Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation |
| NCT02162420 | Not specified | COMPLETED | Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia |
| NCT02720679 | Not specified | RECRUITING | Investigation of the Genetics of Hematologic Diseases |
| NCT03050268 | Not specified | RECRUITING | Familial Investigations of Childhood Cancer Predisposition |
| NCT04959188 | Not specified | COMPLETED | Needs Assessment for Individuals and Families Affected by Dyskeratosis Congenita (DC) and Related Telomere Biology Disorders (TBD) |
| NCT06731036 | Not specified | AVAILABLE | Expanded Access to CD34+ Selection Utilizing Miltenyi CliniMACS Prodigy® for Patients Receiving Peripheral Blood Stem Cell Transplantations and Stem Cell Boosts |
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): dyskeratosis congenita